Showing results (51-60 of 299) with videos related to
Sort By:
Pageof 30
Journal of Acquired Immune Deficiency Syndromes (1999)|December 22, 2006
Changes in the slope of the CD4 cell count increase after initiation of potent antiretroviral treatmentRonald J Bosch, Rui Wang, Florin Vaida, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|August 7, 2003
Viral dynamics and their relations to baseline factors and longer term virologic responses in treatment-naive HIV-1-infected patients receiving abacavir in combination with HIV-1 protease inhibitorsHulin Wu, John Mellors, Ping Ruan, et al.Plos One|March 19, 2013
Decreased IL-7 responsiveness is related to oxidative stress in HIV diseaseMagdalina Kalinowska, Douglas A Bazdar, Michael M Lederman, et al.The Journal of Infectious Diseases|January 29, 2003
Effect of GB virus C coinfection on response to antiretroviral treatment in human immunodeficiency virus-infected patientsBenigno Rodriguez, Ian Woolley, Michael M Lederman, et al.Current Opinion in HIV and AIDS|April 18, 2009
Monitoring clinical trials of therapeutic vaccines in HIV infection: role of treatment interruptionMichael M Lederman, Adam Penn-Nicholson, Shelley F Stone, et al.Scientific Reports|October 29, 2020
Author Correction: A System of Cytokines Encapsulated in ExtraCellular VesiclesWendy Fitzgerald, Michael L Freeman, Michael M Lederman, et al.Retrovirology|December 20, 2008
Topical application of entry inhibitors as "virustats" to prevent sexual transmission of HIV infectionMichael M Lederman, Robin Jump, Heather A Pilch-Cooper, et al.Scientific Reports|June 14, 2018
A System of Cytokines Encapsulated in ExtraCellular VesiclesWendy Fitzgerald, Michael L Freeman, Michael M Lederman, et al.Plos One|July 16, 2011
Resistance to the CCR5 inhibitor 5P12-RANTES requires a difficult evolution from CCR5 to CXCR4 coreceptor useRebecca Nedellec, Mia Coetzer, Michael M Lederman, et al.Journal of Virology|March 26, 2010
"Resistance" to PSC-RANTES revisited: two mutations in human immunodeficiency virus type 1 HIV-1 SF162 or simian-human immunodeficiency virus SHIV SF162-p3 do not confer resistanceRebecca Nedellec, Mia Coetzer, Michael M Lederman, et al.Pageof 30